Adaptive Biotechnologies director granted 15,625 shares

Adaptive Biotechnologies Corp director receives stock award Adaptive Biotechnologies Corp director Michelle Renee Griffin acquired 15,625 shares of common stock on March 4, 2026 through a grant or award at a stated price of $0.00 per share.

Accepted by SEC EDGAR 03/06/2026 - 07:08 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp director receives stock award

Adaptive Biotechnologies Corp director Michelle Renee Griffin acquired 15,625 shares of common stock on March 4, 2026 through a grant or award at a stated price of $0.00 per share. After this transaction, she directly owns a total of 31,019 shares of the company’s common stock.

Insider Trade Summary

Grant/Award: 15,625 shares

Grant/Award 1 txn

Insider GRIFFIN MICHELLE RENEE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,625	$0.00	$0.00

Holdings After Transaction: Common Stock — 31,019 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ADPT director Michelle Renee Griffin report?

Michelle Renee Griffin reported acquiring 15,625 shares of Adaptive Biotechnologies common stock. The shares were received as a grant or award at a stated price of $0.00 per share on March 4, 2026, increasing her direct ownership position in the company.

How many Adaptive Biotechnologies (ADPT) shares does Michelle Renee Griffin now own?

Following the March 4, 2026 transaction, Michelle Renee Griffin directly owns 31,019 shares of Adaptive Biotechnologies common stock. This total reflects the addition of 15,625 shares received as a grant or award reported in the Form 4 insider filing.

Was the ADPT insider transaction a purchase or an award of shares?

The Adaptive Biotechnologies insider transaction was an award of shares, not an open-market purchase. Form 4 data classifies it as a grant or award acquisition, coded “A,” with 15,625 common shares received at a stated price of $0.00 per share on March 4, 2026.

What does transaction code "A" mean in the ADPT Form 4 filing?

Transaction code “A” in the Adaptive Biotechnologies Form 4 indicates a grant, award, or other acquisition. In this case, director Michelle Renee Griffin received 15,625 shares of common stock as a grant or award, rather than buying them on the open market.

Is Michelle Renee Griffin’s ownership in ADPT direct or indirect after this transaction?

After this transaction, Michelle Renee Griffin’s reported ownership in Adaptive Biotechnologies is direct. The Form 4 lists her ownership type as “D” for direct, with 31,019 shares of common stock held following the 15,625-share grant or award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRIFFIN MICHELLE RENEE

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

98109

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/04/2026		A		15,625	A	$0	31,019	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Michelle Renee Griffin by Kyle Piskel, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR